Vascular Therapeutics Overview
- Year Founded
-
1994
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$33.6M
Vascular Therapeutics General Information
Description
Developer of therapeutic agents to prevent and treat life-threatening thrombotic diseases. The company focuses on developing glycotherapeutic agents to treat cardiovascular diseases caused by blood clots (thrombi) such as acute myocardial infarction (or heart attack), angina, stroke, pulmonary embolism and deep vein thrombosis.
Contact Information
Website
www.vtnet.comCorporate Office
- 700 East El Camino Real
- Suite 130
- Mountain View, CA 94040
- United States
Corporate Office
- 700 East El Camino Real
- Suite 130
- Mountain View, CA 94040
- United States
Vascular Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 11-Aug-1999 | $33.6M | Completed | Product Development | ||
| 3. Early Stage VC | 15-Jul-1998 | Completed | Product Development | |||
| 2. Early Stage VC | 17-Sep-1996 | $12.2M | $16.2M | Completed | Product Development | |
| 1. Seed Round | 29-Aug-1994 | $4M | $4M | Completed | Startup |
Vascular Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vascular Therapeutics Patents
Vascular Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-6388060-B1 | Converting polysaccharide to amine salt, dissolving in aprotic solvent and treating with sulfuric acid, then a n,n' carbodiimide, adjusting ph to 12 for a period, then neutralizing, then contacting with sulfating agent | Inactive | 06-Nov-1998 |
Vascular Therapeutics Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AGF Management | Asset Manager | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| EGS Healthcare Capital Partners | PE/Buyout | Minority | ||
| GrowthWorks | Venture Capital | Minority | ||
| Lumira Ventures | Venture Capital | Minority |
Vascular Therapeutics FAQs
-
When was Vascular Therapeutics founded?
Vascular Therapeutics was founded in 1994.
-
Where is Vascular Therapeutics headquartered?
Vascular Therapeutics is headquartered in Mountain View, CA.
-
What industry is Vascular Therapeutics in?
Vascular Therapeutics’s primary industry is Drug Discovery.
-
Is Vascular Therapeutics a private or public company?
Vascular Therapeutics is a Private company.
-
What is the current valuation of Vascular Therapeutics?
The current valuation of Vascular Therapeutics is .
-
What is Vascular Therapeutics’s current revenue?
The current revenue for Vascular Therapeutics is .
-
How much funding has Vascular Therapeutics raised over time?
Vascular Therapeutics has raised $37.8M.
-
Who are Vascular Therapeutics’s investors?
AGF Management, Domain Associates, EGS Healthcare Capital Partners, GrowthWorks, and Lumira Ventures are 5 of 10 investors who have invested in Vascular Therapeutics.
-
When was Vascular Therapeutics acquired?
Vascular Therapeutics was acquired on 11-Aug-1999.
-
Who acquired Vascular Therapeutics?
Vascular Therapeutics was acquired by GlycoDesign.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
